Showing results (531-540 of 812) with videos related to
Sort By:
Pageof 82
United European Gastroenterology Journal|March 25, 2023
Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care centerMathias Jachs, Raphael Sauberer, Alexander Stiegler, et al.JHEP Reports : Innovation in Hepatology|June 26, 2023
Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppressionMathias Jachs, Marlene Panzer, Lukas Hartl, et al.International Journal of Molecular Sciences|March 6, 2021
Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in MiceMatteo Tardelli, Francesca V Bruschi, Claudia D Fuchs, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2013
Long-term outcomes of patients with Wilson disease in a large Austrian cohortSandra Beinhardt, Waltraud Leiss, Albert Friedrich Stättermayer, et al.Journal of Clinical Medicine|May 28, 2022
Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed TomographyConstanze Bardach, Leonie Morski, Katharina Mascherbauer, et al.Journal of Hepatology|January 13, 2024
Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradientMathias Jachs, Lukas Hartl, Benedikt Simbrunner, et al.United European Gastroenterology Journal|May 29, 2021
Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failureLorenz Balcar, Georg Semmler, Katharina Pomej, et al.Hepatology (Baltimore, Md.)|April 29, 2016
Coagulation parameters and major bleeding in critically ill patients with cirrhosisAndreas Drolz, Thomas Horvatits, Kevin Roedl, et al.Plos One|April 15, 2025
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot studyKatharina Pomej, Adrian Frick, Bernhard Scheiner, et al.JHEP Reports : Innovation in Hepatology|July 24, 2023
An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosisLukas Hartl, Benedikt Simbrunner, Mathias Jachs, et al.Pageof 82